Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries

2022, Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet Gastroenterol Hepatol, 7, 796, 10.1016/S2468-1253(22)00124-8 2017 Alberts, 2022, Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review, Lancet Gastroenterol Hepatol, 7, 724, 10.1016/S2468-1253(22)00050-4 Spearman, 2017, Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets, Lancet Gastroenterol Hepatol, 2, 900, 10.1016/S2468-1253(17)30295-9 Lemoine, 2015, Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach, J Hepatol, 62, 469, 10.1016/j.jhep.2014.10.008 Ahmad, 2018, Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries, BMC Infect Dis, 18, 34, 10.1186/s12879-017-2921-8 2016 Connor, 2018 Public Health, 2019 2011 Evlampidou, 2016, Low hepatitis B testing among migrants: a cross-sectional study in a UK city, Br J Gen Pract, 66, e382, 10.3399/bjgp16X684817 Williams, 2013, Screening immigrants for tuberculosis--why not for HBV infection?, Lancet, 381, 2164, 10.1016/S0140-6736(13)61438-5 Aberra, 2019, The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia, J Hepatol, 70, 1065, 10.1016/j.jhep.2019.01.037 Horton, 2020, Offline: COVID-19 is not a pandemic, Lancet, 396, 874, 10.1016/S0140-6736(20)32000-6 Aldridge, 2018, Global patterns of mortality in international migrants: a systematic review and meta-analysis, Lancet, 392, 2553, 10.1016/S0140-6736(18)32781-8 Ochieng, 2013, Black African migrants: the barriers with accessing and utilizing health promotion services in the UK, Eur J Public Health, 23, 265, 10.1093/eurpub/cks063 2017, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 Fattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016/j.jhep.2007.11.011 Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Clin Liver Dis (Hoboken), 12, 33, 10.1002/cld.728 Spearman, 2022, Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa, Lancet Gastroenterol Hepatol, 7, 1036, 10.1016/S2468-1253(22)00041-3 Chu, 2017, Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers, Int J Cancer, 141, 711, 10.1002/ijc.30782 Kimanya, 2021, Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data, PLoS One, 16, 10.1371/journal.pone.0247281 Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 Cargill, 2021, Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations, Gut, 70, 629, 10.1136/gutjnl-2020-322181 Yuen, 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 50, 80, 10.1016/j.jhep.2008.07.023 Wong, 2010, Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers, J Clin Oncol, 28, 1660, 10.1200/JCO.2009.26.2675 Yang, 2011, Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, Lancet Oncol, 12, 568, 10.1016/S1470-2045(11)70077-8 Jung, 2015, Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy, Hepatology, 62, 1757, 10.1002/hep.28115 Wong, 2013, Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment, Gastroenterology, 144, 933, 10.1053/j.gastro.2013.02.002 Johnson, 2014, The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers, Cancer Epidemiol Biomarkers Prev, 23, 144, 10.1158/1055-9965.EPI-13-0870 Wong, 2015, Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?, J Hepatol, 63, 722, 10.1016/j.jhep.2015.05.019 Kramvis, 2016, The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics, Rev Med Virol, 26, 285, 10.1002/rmv.1885 Kramvis, 2007, Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes, Hepatol Res, 37, S9, 10.1111/j.1872-034X.2007.00098.x Spearman, 2021, Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa, Lancet Gastroenterol Hepatol, 6, 1036, 10.1016/S2468-1253(21)00275-2 Chang, 2010, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology, 52, 886, 10.1002/hep.23785 Nguyen, 2019, Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with Tenofovir-A propensity Score-Matched study, J Infect Dis, 219, 10, 10.1093/infdis/jiy391 Wang, 2020, Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis, Gut Liver, 14, 232, 10.5009/gnl18546 Arends, 2015, Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians, Gut, 64, 1289, 10.1136/gutjnl-2014-307023 Papatheodoridis, 2015, Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort, J Viral Hepat, 22, 120, 10.1111/jvh.12283 Papatheodoridis, 2017, The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B, Hepatology, 66, 1444, 10.1002/hep.29320 Choi, 2021, Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 19, 246, 10.1016/j.cgh.2020.05.008 Hsu, 2020, Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B, Am J Gastroenterol, 115, 271, 10.14309/ajg.0000000000000428 Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016 Dusheiko, 2019, An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans, J Hepatol, 70, 1046, 10.1016/j.jhep.2019.03.009 2015 Yoshida, 2019, Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe, J Hepatol, 70, 1295, 10.1016/j.jhep.2019.03.008 Desalegn, 2018, Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia, BMC Med, 16, 234, 10.1186/s12916-018-1229-x Cuenca-Gomez, 2018, Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice, BMC Infect Dis, 18, 568, 10.1186/s12879-018-3469-y Peralta, 2011, Racial and ethnic differences in kidney function decline among persons without chronic kidney disease, J Am Soc Nephrol, 22, 1327, 10.1681/ASN.2010090960 Cappuccio, 1997, Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London, Heart, 78, 555, 10.1136/hrt.78.6.555 Villa, 2018, Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana, J Infect, 76, 515 Surial, 2020, Brief report: switching from TDF to TAF in HIV/HBV-coinfected individuals with renal dysfunction-A prospective cohort study, J Acquir Immune Defic Syndr, 85, 227, 10.1097/QAI.0000000000002429 Mallon, 2021, Weight gain before and after switch from TDF to TAF in a U.S. cohort study, J Int AIDS Soc, 24 Byrne, 2014, Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection, J Hepatol, 61, 210, 10.1016/j.jhep.2014.04.001 Eggemoen, 2013, Vitamin D status in recently arrived immigrants from Africa and Asia: a cross-sectional study from Norway of children, adolescents and adults, BMJ Open, 3, 10.1136/bmjopen-2013-003293 Mokaya, 2020, Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults, J Clin Virol, 129, 10.1016/j.jcv.2020.104548 Buster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterology, 137, 2002, 10.1053/j.gastro.2009.08.061 Agarwal, 2022, A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV ‘cure’, J Hepatol, 77, 245, 10.1016/j.jhep.2022.03.006 van Bommel, 2021, Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B, Hepatol Commun, 5, 1632, 10.1002/hep4.1708 Hadziyannis, 2012, Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir, Gastroenterology, 143, 629, 10.1053/j.gastro.2012.05.039 Berg, 2017, Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study, J Hepatol, 67, 918, 10.1016/j.jhep.2017.07.012 Papatheodoridis, 2016, Discontinuation of oral antivirals in chronic hepatitis B: a systematic review, Hepatology, 63, 1481, 10.1002/hep.28438 Hall, 2022, Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis, Gut, 71, 1629 Liu, 2019, The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review, Hepatology, 70, 1045, 10.1002/hep.30474 Sonneveld, 2022, Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels, J Hepatol, 76, 1042, 10.1016/j.jhep.2022.01.007 Jeng, 2013, Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients, Hepatology, 58, 1888, 10.1002/hep.26549 Yeo, 2019, Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis, Gastroenterology, 156, 635, 10.1053/j.gastro.2018.10.027 Shimakawa, 2016, Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia, Gut, 65, 2007, 10.1136/gutjnl-2015-309892 Hwenda, 2022, The African Medicines Agency: the key to unlocking clinical research in Africa, Lancet Glob Health, 10, e1088, 10.1016/S2214-109X(22)00243-1 Toto, 2020, Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study, Trials, 21, 680, 10.1186/s13063-020-04620-8 Hanass-Hancock, 2021, Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa, Trials, 22, 897, 10.1186/s13063-021-05792-7 Karita, 2009, CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa, PLoS One, 4, 10.1371/journal.pone.0004401 Neuschwander-Tetri, 2008, Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels, Arch Intern Med, 168, 663, 10.1001/archinternmed.2007.131 Haddy, 1999, Benign ethnic neutropenia: what is a normal absolute neutrophil count?, J Lab Clin Med, 133, 15, 10.1053/lc.1999.v133.a94931 Lakhotia, 2019, Natural history of benign ethnic neutropenia in individuals of African ancestry, Blood Cells Mol Dis, 77, 12, 10.1016/j.bcmd.2019.01.009 Vastola, 2018, Laboratory eligibility criteria as potential barriers to participation by Black men in prostate cancer clinical trials, JAMA Oncol, 4, 413, 10.1001/jamaoncol.2017.4658 Tian, 2022, Feasibility of hepatitis B elimination in high-income countries with ongoing immigration, J Hepatol, 77, 947, 10.1016/j.jhep.2022.04.014 Kim, 2021, Improving care of migrants is key for viral hepatitis elimination in Europe, Bull World Health Organ, 99, 280, 10.2471/BLT.20.260919 Martin, 2019, Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation, BMJ Open, 9, 10.1136/bmjopen-2019-030183 Hargreaves, 2020, Delivering multi-disease screening to migrants for latent TB and blood-borne viruses in an emergency department setting: a feasibility study, Trav Med Infect Dis, 36, 10.1016/j.tmaid.2020.101611 Shimakawa, 2022, Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings, Clin Gastroenterol Hepatol, 10.1016/j.cgh.2022.05.026 Freeland, 2020, Barriers to hepatitis B screening and prevention for African immigrant populations in the United States: a qualitative study, Viruses, 12, 10.3390/v12030305 Adjei, 2020, “To die is better than to tell”: reasons for and against disclosure of chronic hepatitis B status in Ghana, BMC Public Health, 20, 663, 10.1186/s12889-020-08811-5 Mude, 2019, A qualitative investigation of barriers, support-seeking and coping among South Sudanese people with chronic hepatitis B in Australia, Aust J Prim Health, 10.1071/PY19015 Saunders, 2021, Healthcare utilization among migrants to the UK: cross-sectional analysis of two national surveys, J Health Serv Res Pol, 26, 54, 10.1177/1355819620911392 Lai, 1998, A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group, N Engl J Med, 339, 61, 10.1056/NEJM199807093390201 Hadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B, N Engl J Med, 348, 800, 10.1056/NEJMoa021812 Chang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056/NEJMoa051285 Marcellin, 2008, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, 2442, 10.1056/NEJMoa0802878 Buti, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 196, 10.1016/S2468-1253(16)30107-8 Chan, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 185, 10.1016/S2468-1253(16)30024-3 Bazinet, 2020, Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy, Gastroenterology, 158, 2180, 10.1053/j.gastro.2020.02.058